HALB - Halberd announces second mAb against covid-19 spike protein

Halberd's ([[HALB]] +8.2%) research has produced a second monoclonal antibody (mAb) against the Covid-19 spike protein after initial testing displayed a stronger affinity for the SARS-CoV-2 antigen than Halberd's initial antibody.Testing will continue on each antibody to establish potency and specificity as well as a potential "cocktail mix" of both antibodies acting in concert."We believe having multiple antibodies available not only increases our product application options, but also their effectiveness, when used in combination," CEO William Hartman said.

For further details see:

Halberd announces second mAb against covid-19 spike protein